Abstract
With the advent of thalidomide, the treatment of multiple myeloma was revolutionized. The drug showed excellent response rates in both previously untreated and relapsed/refractory patients. However, treatment-related toxicities such as somnolence, constipation, and neuropathy were a major limitation to its use. Lenalidomide, a thalidomide analogue, was developed with the hope of improving both the efficacy and toxicity profile of thalidomide and has subsequently shown significant clinical activity in patients with multiple myeloma. Though approved only for relapsed/refractory patients till date, clinical trials using lenalidomide with or without combinations have shown great efficacy in newly diagnosed, as a maintenance therapy and even asymptomatic myeloma. The recent introduction of another thalidomide analogue-pomalidomide has shown significant activity and a great potential for use in relapsed/refractory myeloma including those refractory to lenalidomide and bortezomib.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
References
Muller GW, Chen R, Huang SY et al (1999) Amino-substituted thalidomide analogs: potent inhibitors of TNF-alpha production. Bioorg Med Chem Lett 9(11):1625–1630
Kumar SK, Rajkumar SV, Dispenzieri A et al (2008) Improved survival in multiple myeloma and the impact of novel therapies. Blood 111(5):2516–2520
Corral LG, Haslett PA, Muller GW et al (1999) Differential cytokine modulation and T cell activation by two distinct classes of thalidomide analogues that are potent inhibitors of TNF-alpha. J Immunol 163(1):380–386
Lichtenstein A, Tu Y, Fady C et al (1995) Interleukin-6 inhibits apoptosis of malignant plasma cells. Cell Immunol 162(2):248–255
Breitkreutz I, Raab MS, Vallet S et al (2008) Lenalidomide inhibits osteoclastogenesis, survival factors and bone-remodeling markers in multiple myeloma. Leukemia 22(10):1925–1932
Geitz H, Handt S, Zwingenberger K (1996) Thalidomide selectively modulates the density of cell surface molecules involved in the adhesion cascade. Immunopharmacology 31(2–3):213–221
Richardson PG, Schlossman RL, Weller E et al (2002) Immunomodulatory drug CC-5013 overcomes drug resistance and is well tolerated in patients with relapsed multiple myeloma. Blood 100(9):3063–3067
Melchert M, List A (2007) The thalidomide saga. Int J Biochem Cell Biol 39(7–8):1489–1499
Sharpe AH, Abbas AK (2006) T-cell costimulation–biology, therapeutic potential, and challenges. N Engl J Med 355(10):973–975
Dredge K, Marriott JB, Todryk SM et al (2002) Protective antitumor immunity induced by a costimulatory thalidomide analog in conjunction with whole tumor cell vaccination is mediated by increased Th1-type immunity. J Immunol 168(10):4914–4919
Stirling D (2001) Thalidomide: a novel template for anticancer drugs. Semin Oncol 28(6):602–606
Hayashi T, Hideshima T, Akiyama M et al (2005) Molecular mechanisms whereby immunomodulatory drugs activate natural killer cells: clinical application. Br J Haematol 128(2):192–203
D’Amato RJ, Loughnan MS, Flynn E et al (1994) Thalidomide is an inhibitor of angiogenesis. Proc Natl Acad Sci USA 91(9):4082–4085
Dredge K, Marriott JB, Macdonald CD et al (2002) Novel thalidomide analogues display anti-angiogenic activity independently of immunomodulatory effects. Br J Cancer 87(10):1166–1172
Shadduck RK, Latsko JM, Rossetti JM et al (2007) Recent advances in myelodysplastic syndromes. Exp Hematol 35(4 Suppl 1):137–143
Gupta D, Treon SP, Shima Y et al (2001) Adherence of multiple myeloma cells to bone marrow stromal cells upregulates vascular endothelial growth factor secretion: therapeutic applications. Leukemia 15(12):1950–1961
Teo SK (2005) Properties of thalidomide and its analogues: implications for anticancer therapy. AAPS J 7(1):E14–E19
Dredge K, Horsfall R, Robinson SP et al (2005) Orally administered lenalidomide (CC-5013) is anti-angiogenic in vivo and inhibits endothelial cell migration and Akt phosphorylation in vitro. Microvasc Res 69(1–2):56–63
Gandhi AK, Kang J, Naziruddin S et al (2006) Lenalidomide inhibits proliferation of Namalwa CSN.70 cells and interferes with Gab1 phosphorylation and adaptor protein complex assembly. Leuk Res 30(7):849–858
Bartlett JB, Dredge K, Dalgleish AG (2004) The evolution of thalidomide and its IMiD derivatives as anticancer agents. Nat Rev Cancer 4(4):314–322
Verhelle D, Corral LG, Wong K et al (2007) Lenalidomide and CC-4047 inhibit the proliferation of malignant B cells while expanding normal CD34+ progenitor cells. Cancer Res 67(2):746–755
Hideshima T, Chauhan D, Shima Y et al (2000) Thalidomide and its analogs overcome drug resistance of human multiple myeloma cells to conventional therapy. Blood 96(9):2943–2950
Mitsiades N, Mitsiades CS, Poulaki V et al (2002) Apoptotic signaling induced by immunomodulatory thalidomide analogs in human multiple myeloma cells: therapeutic implications. Blood 99(12):4525–4530
Mitsiades CS, Mitsiades NS, Richardson PG et al (2007) Multiple myeloma: a prototypic disease model for the characterization and therapeutic targeting of interactions between tumor cells and their local microenvironment. J Cell Biochem 101(4):950–968
RevAssist® for Prescribers. http://www.revlimid.com. Accessed april 2010 (2010)
Dimopoulos MA, Chen C, Spencer A et al (2009) Long-term follow-up on overall survival from the MM-009 and MM-010 phase III trials of lenalidomide plus dexamethasone in patients with relapsed or refractory multiple myeloma. Leukemia 23(11):2147–2152
Chen C, Reece DE, Siegel D et al (2009) Expanded safety experience with lenalidomide plus dexamethasone in relapsed or refractory multiple myeloma. Br J Haematol 146(2):164–170
Richardson PG, Blood E, Mitsiades CS et al (2006) A randomized phase 2 study of lenalidomide therapy for patients with relapsed or relapsed and refractory multiple myeloma. Blood 108(10):3458–3464
Richardson P, Jagannath S, Hussein M et al (2009) Safety and efficacy of single-agent lenalidomide in patients with relapsed and refractory multiple myeloma. Blood 114(4):772–778
Weber DM, Chen C, Niesvizky R et al (2007) Lenalidomide plus dexamethasone for relapsed multiple myeloma in North America. N Engl J Med 357(21):2133–2142
Dimopoulos M, Spencer A, Attal M et al (2007) Lenalidomide plus dexamethasone for relapsed or refractory multiple myeloma. N Engl J Med 357(21):2123–2132
Richardson PG, Weller E, Lonial S et al (2010) Lenalidomide, bortezomib, and dexamethasone combination therapy in patients with newly diagnosed multiple myeloma. Blood 116(5):679–686
Richardson PG, Siegel D, Baz R et al (2010a) A phase 1/2 multi-center, randomized, open label dose escalation study to determine the maximum tolerated dose, safety, and efficacy of pomalidomide alone or in combination with low-dose dexamethasone in patients with relapsed and refractory multiple myeloma who have received prior treatment that includes lenalidomide and bortezomib. ASH Annual Meeting Abstracts 116(21):864
Dimopoulos MA, Kastritis E, Christoulas D et al (2010) Treatment of patients with relapsed/refractory multiple myeloma with lenalidomide and dexamethasone with or without bortezomib: prospective evaluation of the impact of cytogenetic abnormalities and of previous therapies. Leukemia 24(10):1769–1778
Zonder JA, Crowley J, Hussein MA et al (2010) Lenalidomide and high-dose dexamethasone compared with dexamethasone as initial therapy for multiple myeloma: a randomized Southwest Oncology Group trial (S0232). Blood 116(26):5838–5841
Rajkumar SV, Jacobus S, Callander NS et al (2010) Lenalidomide plus high-dose dexamethasone versus lenalidomide plus low-dose dexamethasone as initial therapy for newly diagnosed multiple myeloma: an open-label randomised controlled trial. Lancet Oncol 11(1):29–37
Gay F, Hayman SR, Lacy MQ et al (2010) Lenalidomide plus dexamethasone versus thalidomide plus dexamethasone in newly diagnosed multiple myeloma: a comparative analysis of 411 patients. Blood 115(7):1343–1350
Palumbo A, Falco P, Corradini P et al (2007) Melphalan, prednisone, and lenalidomide treatment for newly diagnosed myeloma: a report from the GIMEMA—Italian multiple myeloma network. J Clin Oncol 25(28):4459–4465
Lonial S, Baz R, Swern AS et al (2009) Neutropenia is a predictable and early event in affected patients with relapsed/refractory multiple myeloma treated with lenalidomide in combination with dexamethasone. ASH Annual Meeting Abstracts 114(22):2879-
Ishak J, Dimopoulos MA, Weber D et al (2008) Declining rates of adverse events and dose modifications with lenalidomide in combination with dexamethasone. ASH Annual Meeting Abstracts 112(11):3708-
Rajkumar SV, Blood E (2006) Lenalidomide and venous thrombosis in multiple myeloma. N Engl J Med 354(19):2079–2080
Zonder JA (2006) Thrombotic complications of myeloma therapy. Hematology 2006(1):348–355
Cavallo F, Raimondo FD, Harda I et al (2010) A phase III study of enoxaparin vs aspirin as thromboprophylaxis for newly diagnosed myeloma patients treated with lenalidomide-based regimen. ASH Annual Meeting Abstracts 116(21):1092-
Klein U, Kosely F, Hillengass J et al (2009) Effective prophylaxis of thromboembolic complications with low molecular weight heparin in relapsed multiple myeloma patients treated with lenalidomide and dexamethasone. Ann Hematol 88(1):67–71
Kneppers E, Lokhorst HM, Eeltink CM et al (2010) Analysis of efficacy and prognostic factors of lenalidomide treatment as part of a Dutch compassionate use program. Clin Lymphoma Myeloma Leuk 10(2):138–143
Palumbo A, Rajkumar SV, Dimopoulos MA et al (2008) Prevention of thalidomide- and lenalidomide-associated thrombosis in myeloma. Leukemia 22(2):414–423
Menon SP, Rajkumar SV, Lacy M et al (2008) Thromboembolic events with lenalidomide-based therapy for multiple myeloma. Cancer 112(7):1522–1528
Minnema MC, Breitkreutz I, Auwerda JJ et al (2004) Prevention of venous thromboembolism with low molecular-weight heparin in patients with multiple myeloma treated with thalidomide and chemotherapy. Leukemia 18(12):2044–2046
Dimopoulos MA, Palumbo A, Attal M et al (2011) Optimizing the use of lenalidomide in relapsed or refractory multiple myeloma: consensus statement. Leukemia 25(5):749–760
Delforge M, Facon T, Bravo M-L et al (2009) Lenalidomide plus dexamethasone has similar tolerability and efficacy in treatment of relapsed/refractory multiple myeloma patients with or without history of neuropathy. ASH Annual Meeting Abstracts 114(22):3873-
Sviggum HP, Davis MD, Rajkumar SV et al (2006) Dermatologic adverse effects of lenalidomide therapy for amyloidosis and multiple myeloma. Arch Dermatol 142(10):1298–1302
Darabi K, Kantamnei S, Wiernik PH (2006) Lenalidomide-induced warm autoimmune hemolytic anemia. J Clin Oncol 24(35):e59
Harousseau JL, Dimopoulos MA, Wang M et al (2010) Better quality of response to lenalidomide plus dexamethasone is associated with improved clinical outcomes in patients with relapsed or refractory multiple myeloma. Haematologica 95(10):1738–1744
San-Miguel JF, Dimopoulos MA, Stadtmauer EA, et al (2011) Effects of lenalidomide and dexamethasone treatment duration on survival in patients with relapsed or refractory multiple myeloma treated with lenalidomide and dexamethasone. Clin Lymphoma Myeloma Leuk 11(1):38–43
Reece D, Song KW, Fu T et al (2009) Influence of cytogenetics in patients with relapsed or refractory multiple myeloma treated with lenalidomide plus dexamethasone: adverse effect of deletion 17p13. Blood 114(3):522–525
Orlowski RZ, Nagler A, Sonneveld P et al (2007) Randomized phase III study of pegylated liposomal doxorubicin plus bortezomib compared with bortezomib alone in relapsed or refractory multiple myeloma: combination therapy improves time to progression. J Clin Oncol 25(25):3892–3901
Anderson KC, Jagannath S, Jakubowiak A et al (2009) Lenalidomide, bortezomib, and dexamethasone in relapsed/refractory multiple myeloma (MM): Encouraging outcomes and tolerability in a phase II study. ASCO Meeting Abstracts 27(15S):8536
Richardson P, Jagannath S, Jakubowiak A et al (2008) Lenalidomide, bortezomib, and dexamethasone in patients with relapsed or relapsed/refractory multiple myeloma (MM): encouraging response rates and tolerability with correlation of outcome and adverse cytogenetics in a phase II study. ASH Annual Meeting Abstracts 112(11):1742.
Zonder JA, Barlogie B, Durie BGM et al (2006) Thrombotic complications in patients with newly diagnosed multiple myeloma treated with lenalidomide and dexamethasone: benefit of aspirin prophylaxis. Blood 108(1):403–404
Baz R, Patel M, Finley-Oliver E et al (2010) Single agent lenalidomide in newly diagnosed multiple myeloma: a retrospective analysis. Leuk Lymphoma 51(6):1015–1019
Palumbo A, Falco P, Benevolo G et al (2010) A multicenter, open label study of oral lenalidomide and prednisone (RP) followed by oral lenalidomide melphalan and prednisone (MPR) and oral lenalidomide maintenance in newly diagnosed elderly multiple myeloma patients. ASH Annual Meeting Abstracts 116(21):1940
Attal M, Harousseau JL, Leyvraz S et al (2006) Maintenance therapy with thalidomide improves survival in patients with multiple myeloma. Blood 108(10):3289–3294
Barlogie B, Pineda-Roman M, van Rhee F et al (2008) Thalidomide arm of total therapy 2 improves complete remission duration and survival in myeloma patients with metaphase cytogenetic abnormalities. Blood 112(8):3115–3121
Barlogie B, Tricot G, Anaissie E et al (2006) Thalidomide and hematopoietic-cell transplantation for multiple myeloma. N Engl J Med 354(10):1021–1030
Spencer A, Prince HM, Roberts AW et al (2009) Consolidation therapy with low-dose thalidomide and prednisolone prolongs the survival of multiple myeloma patients undergoing a single autologous stem-cell transplantation procedure. J Clin Oncol 27(11):1788–1793
McCarthy PL, Owzar K, Anderson KC et al (2010) Phase III intergroup study of lenalidomide versus placebo maintenance therapy following single autologous stem cell transplant (ASCT) for multiple myeloma (MM): CALGB 100104. ASCO Meeting Abstracts 28 (15_suppl):8017
Attal M, Cristini C, Marit G et al (2010) Lenalidomide maintenance after transplantation for myeloma. ASCO Meeting Abstracts 28(15_suppl):8018
International Myeloma Working Group (2003) Criteria for the classification of monoclonal gammopathies, multiple myeloma and related disorders: a report of the International Myeloma Working Group. Br J Haematol 121(5):749–757
Kyle RA, Remstein ED, Therneau TM et al (2007) Clinical course and prognosis of smoldering (asymptomatic) multiple myeloma. N Engl J Med 356(25):2582–2590
Barlogie B, van Rhee F, Shaughnessy JD Jr et al (2008) Seven-year median time to progression with thalidomide for smoldering myeloma: partial response identifies subset requiring earlier salvage therapy for symptomatic disease. Blood 112(8):3122–3125
Rajkumar SV, Gertz MA, Lacy MQ et al (2003) Thalidomide as initial therapy for early-stage myeloma. Leukemia 17(4):775–779
Weber D, Rankin K, Gavino M et al (2003) Thalidomide alone or with dexamethasone for previously untreated multiple myeloma. J Clin Oncol 21(1):16–19
Mateos M-V, Lopez-Corral L, Hernandez MT et al. (2009) Multicenter, randomized, open-label, phase III trial of lenalidomide-dexamethasone (len/dex) vs therapeutic abstention in smoldering multiple myeloma at high risk of progression to symptomatic mm: results of the first interim analysis. ASH Annual Meeting Abstracts 114(22):614
Galustian C, Meyer B, Labarthe MC et al (2009) The anti-cancer agents lenalidomide and pomalidomide inhibit the proliferation and function of T regulatory cells. Cancer Immunol Immunother 58(7):1033–1045
Schey SA, Fields P, Bartlett JB et al (2004) Phase I study of an immunomodulatory thalidomide analog, CC-4047, in relapsed or refractory multiple myeloma. J Clin Oncol 22(16):3269–3276
Anderson G, Gries M, Kurihara N et al (2006) Thalidomide derivative CC-4047 inhibits osteoclast formation by down-regulation of PU.1. Blood 107(8):3098–3105
Ferguson GD, Jensen-Pergakes K, Wilkey C et al (2007) Immunomodulatory drug CC-4047 is a cell-type and stimulus-selective transcriptional inhibitor of cyclooxygenase 2. J Clin Immunol 27(2):210–220
Streetly MJ, Gyertson K, Daniel Y et al (2008) Alternate day pomalidomide retains anti-myeloma effect with reduced adverse events and evidence of in vivo immunomodulation. Br J Haematol 141(1):41–51
Lacy MQ, Hayman SR, Gertz MA et al (2009) Pomalidomide (CC4047) plus low-dose dexamethasone as therapy for relapsed multiple myeloma. J Clin Oncol 27(30):5008–5014
Lacy MQ, Hayman SR, Gertz MA et al (2010) Pomalidomide (CC4047) plus low dose dexamethasone (Pom/dex) is active and well tolerated in lenalidomide refractory multiple myeloma (MM). Leukemia 24(11):1934–1939
Lacy M, Mandrekar S, Gertz MAA et al (2010a) Pomalidomide plus low-dose dexamethasone in myeloma refractory to both bortezomib and lenalidomide: comparison of two dosing strategies in dual-refractory disease. ASH Annual Meeting Abstracts 116(21):863-
Leleu X, Attal M, Moreau P et al (2010) Phase 2 study of 2 modalities of pomalidomide (CC4047) plus low-dose dexamethasone as therapy for relapsed multiple myeloma. IFM 2009–02. ASH Annual Meeting Abstracts 116(21):859-
Begna KH, Mesa RA, Pardanani A et al (2011) A phase-2 trial of low-dose pomalidomide in myelofibrosis. Leukemia 25(2):301–304
Streetly M, Stewart O, Gyertson K et al (2009) Pomalidomide monotherapy for relapsed myeloma is associated with excellent responses and prolonged progression free and overall survival. ASH Annual Meeting Abstracts 114(22):3878
Short KD, Rajkumar SV, Larson D et al (2011) Incidence of extramedullary disease in patients with multiple myeloma in the era of novel therapy, and the activity of pomalidomide on extramedullary myeloma. Leukemia 25(6):906–908
Baz R, Walker E, Karam MA, et al (2006) Lenalidomide and pegylated liposomal doxorubicin-based chemotherapy for relapsed or refractory multiple myeloma: safety and efficacy. Ann Oncol. 17(12):1766–1771
Knop S, Gerecke C, Liebisch P, et al (2009) Lenalidomide, adriamycin, and dexamethasone (RAD) in patients with relapsed and refractory multiple myeloma: a report from the German Myeloma Study Group DSMM (Deutsche Studiengruppe Multiples Myelom). Blood 113(18):4137–4143
Morgan GJ, Schey SA, Wu P, et al (2007) Lenalidomide (Revlimid), in combination with cyclophosphamide and dexamethasone (RCD), is an effective and tolerated regimen for myeloma patients. Br J Haematol 137(13):268–269
Schey SA, Morgan GJ, Ramasamy K, et al (2010) The addition of cyclophosphamide to lenalidomide and dexamethasone in multiply relapsed/refractory myeloma patients; a phase I/II study. British Journal of Haematology 150(3):326–333
Reece DE, Masih-Khan E, Khan A, et al (2010) Phase I-II Trial of Oral Cyclophosphamide, Prednisone and Lenalidomide (Revlimid(R)) (CPR) for the Treatment of Patients with Relapsed and Refractory Multiple Myeloma. ASH Annual Meeting Abstracts 116:3055
Lacy MQ, Gertz MA, Dispenzieri A, et al (2007) Long-term Results of Response to Therapy, Time to Progression, and Survival With Lenalidomide Plus Dexamethasone in Newly Diagnosed Myeloma. Mayo Clinic Proceedings 82(10):1179–1184
Niesvizky R, Jayabalan DS, Christos PJ, et al (2008) BiRD (Biaxin [clarithromycin]/Revlimid [lenalidomide]/dexamethasone) combination therapy results in high complete- and overall-response rates in treatment-naive symptomatic multiple myeloma. Blood 111(3):1101–1109
Kumar SK, Flinn I, Noga SJ, et al (2010) Bortezomib, dexamethasone, cyclophosphamide and lenalidomide combination for newly diagnosed multiple myeloma: phase 1 results from the multicenter EVOLUTION study. Leukemia 24(7):1350–1356
Author information
Authors and Affiliations
Corresponding author
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2013 Springer Science+Business Media New York
About this chapter
Cite this chapter
Singla, A., Kumar, S. (2013). Newer IMiDs. In: Munshi, N., Anderson, K. (eds) Advances in Biology and Therapy of Multiple Myeloma. Springer, New York, NY. https://doi.org/10.1007/978-1-4614-5260-7_8
Download citation
DOI: https://doi.org/10.1007/978-1-4614-5260-7_8
Published:
Publisher Name: Springer, New York, NY
Print ISBN: 978-1-4614-5259-1
Online ISBN: 978-1-4614-5260-7
eBook Packages: Biomedical and Life SciencesBiomedical and Life Sciences (R0)